CARCINOMA, RENAL CELL

This early-stage study tested a new drug called DFF332 in people with advanced clear cell kidney cancer. The drug works by blocking a protein (HIF2α) that helps some cancers grow. Researchers gave DFF332 alone or with other drugs to see if it was safe and could shrink tumors. The…

This study tested whether adding atezolizumab to cabozantinib works better than cabozantinib alone for people with advanced kidney cancer that got worse after immunotherapy. The trial planned to enroll 522 participants but was terminated early. The goal was to see if the combinat…

This study tested a drug called SGI-110 (guadecitabine) in people aged 12 and older with certain rare cancers that did not respond to other treatments. The cancers included wild-type GIST (a stomach or intestinal tumor), pheochromocytoma/paraganglioma (adrenal or nerve tumors), a…

This early-phase study tested a new drug called QEQ278 in 30 adults with advanced lung, kidney, esophageal, or head and neck cancers that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was terminated early, so…

This study tested two new drug combinations for people with advanced clear cell kidney cancer that had already been treated. The goal was to see if adding the experimental drug NKT2152 to standard therapies could shrink tumors or slow the disease. The trial was stopped early, so …